Sign up to receive more information about YUTREPIA

Sign Up

YUTREPIA is designed to deliver prostacyclin therapy with ease

 

YUTREPIA is unique

YUTREPIA is an inhaled treprostinil dry powder that is indicated to improve exercise ability in patients with PAH (WHO Group 1) or in patients with PH-ILD (WHO Group 3). The active ingredient in YUTREPIA, treprostinil, is well studied and proven to be safe and effective.

Diagram showing how smaller drug particles have the potential to get deeper into the lungs

YUTREPIA is delivered directly into the lungs, where it's needed

YUTREPIA is made using a novel technology that produces drug particles that have the same size and shape and are free-flowing, so they may get deep into the lungs.

In contrast to conventional dry powders, delivery of YUTREPIA powder does not depend on strong inhalation by patients to break up and disperse medication.

WHO = World Health Organization

 

YUTREPIA is delivered by an easy-to-use and convenient low-effort inhaler

YUTREPIA is a small pocket-sized inhaler icon

YUTREPIA consists of a small, pocket-sized inhaler and replaceable drug capsules.

No refrigeration is needed for YUTREPIA icon

No refrigeration is needed—YUTREPIA is stored at room temperature.

The inhaler is not position-dependent icon

The inhaler does not need to be prepared and used in a specific position, reducing the chance of making an error or spilling the drug.

The easy-to-use, low-effort inhaler icon

The easy-to-use, low-effort inhaler has been trusted by doctors and people with lung conditions for decades.

 

How treatment with YUTREPIA may help

In a clinical study, patients with PH-ILD who took inhaled treprostinil showed improvement in important clinical measures*

Improved 6-minute walk test icon

INCREASED HOW FAR THEY COULD WALK IN A 6-MINUTE TEST

Patients who took inhaled treprostinil solution walked 21 meters farther than those who did not take inhaled treprostinil.

Reduced risk test icon

REDUCED THE RISK OF PH-ILD GETTING WORSE

Patients taking inhaled treprostinil solution had 39% overall reduction in the risk of a clinical worsening event during the study.

* In a 16-week PH-ILD clinical study, 6MWDs were compared for people who took inhaled Treprostinil solution and those who took a placebo.

Inhaled treprostinil is the ONLY therapy proven to help patients with PH-ILD

100%

of patients in a clinical study who switched from the TYVASO® nebulizer preferred the YUTREPIA device when asked after 4 months of use.*

Female walking into a room with groceries; not an actual patient

TYVASO® is a registered trademark of United Therapeutics Corporation.

*Data from the INSPIRE clinical trial: 49 out of 49 participants preferred the YUTREPIA device over the TYVASO® nebulizer—40 participants strongly preferred the YUTREPIA device, and 9 preferred it.

Currently, no studies have been performed in PH-ILD to determine patient preference.

 

Know the possible side effects of YUTREPIA

YUTREPIA was well studied in patients with PAH and most side effects were generally mild to moderate in severity

The most common side effects are:

  • Cough
  • Headache
  • Throat irritation and pain
  • Nausea
  • Reddening of the face and neck (flushing)
  • Fainting or loss of consciousness
  • Dizziness
  • Diarrhea
  • Shortness of breath

This safety profile is consistent with that reported for inhaled treprostinil solution in clinical studies of patients with PAH and in separate studies of those with PH-ILD

These are not all the possible side effects of YUTREPIA. Be sure to tell your healthcare team about any side effect that bothers you. Continue to take YUTREPIA as prescribed unless you are told to stop by your healthcare team.

Call your doctor for medical advice about side effects or if you have trouble breathing.

Talk to your healthcare team about how to manage any side effects.